» Articles » PMID: 28778498

Prognostic Role of Nectin-4 Expression in Luminal B (HER2 Negative) Breast Cancer

Overview
Specialty Pathology
Date 2017 Aug 6
PMID 28778498
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Nectins are Ca2-independent immunoglobulin (Ig) superfamily proteins that participate in the organization of epithelial and endothelial junctions and regulate several cellular activities including the entry of some viruses. Nectin-4 has recently been shown as a metastasis-associated protein in several cancers. In the following study, we have evaluated the expression of Nectin-4 inthe luminal B HER2 negative subtype breast cancer. The study group consisted of 147 patients presenting with primary unilateral breast carcinoma with no evidence of distant metastases. Nectin-4 protein expression was assessed by immunohistochemistry and the results were correlated with the clinical data using Kaplan-Meier curves, univariate and multivariate stepwise proportional-hazard analysis (Cox model). Nectin-4 overexpression was significantly correlated with the tumour size (p<0.05; Fisher's Exact Test), also Nectin-4 expression was negatively associated with overall survival, disease free survival and distant relapse free survival with the same significance (p<0,001; Kaplan-Meier, Cox model). We did not find statistically significant correlation between Nectin-4 and age, ER, PR, age, lymph node metastasis, tumour differentiation, histologicalsubtype and Ki-67proliferation index. We suggest that Nectin-4 is a relevant prognostic factor and a therapeutic target in luminalB (HER2 negative) breast cancer.

Citing Articles

Targeted therapeutic strategies for Nectin-4 in breast cancer: Recent advances and future prospects.

Wang Y, Li G, Wang H, Qi Q, Wang X, Lu H Breast. 2024; 79:103838.

PMID: 39577073 PMC: 11616553. DOI: 10.1016/j.breast.2024.103838.


Therapeutic prospects of nectin-4 in cancer: applications and value.

Li K, Zhou Y, Zang M, Jin X, Li X Front Oncol. 2024; 14:1354543.

PMID: 38606099 PMC: 11007101. DOI: 10.3389/fonc.2024.1354543.


Production and characterization of single-chain variable fragment antibodies targeting the breast cancer tumor marker nectin-4.

Liu C, Leu S, Lee C, Lin C, Wang W, Tsai B Front Immunol. 2024; 14:1292019.

PMID: 38288120 PMC: 10822971. DOI: 10.3389/fimmu.2023.1292019.


Anti-tumor activity of a recombinant measles virus against canine lung cancer cells.

Tamura K, Fujiyuki T, Moritoh K, Akimoto H, Iizuka K, Sato H Sci Rep. 2023; 13(1):18168.

PMID: 37875555 PMC: 10597997. DOI: 10.1038/s41598-023-42305-9.


Clinical Significance of Nectins in HCC and Other Solid Malignant Tumors: Implications for Prognosis and New Treatment Opportunities-A Systematic Review.

Klekowski J, Zielinska D, Hofman A, Zajdel N, Gajdzis P, Chabowski M Cancers (Basel). 2023; 15(15).

PMID: 37568798 PMC: 10416819. DOI: 10.3390/cancers15153983.